MCID: PRS039
MIFTS: 45

Prostate Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostate Adenocarcinoma

MalaCards integrated aliases for Prostate Adenocarcinoma:

Name: Prostate Adenocarcinoma 12 13 14
Adenocarcinoma of Prostate 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2526
NCIt 47 C2919
SNOMED-CT 64 399490008
UMLS 69 C0007112

Summaries for Prostate Adenocarcinoma

Disease Ontology : 12 A prostate carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Prostate Adenocarcinoma, also known as adenocarcinoma of prostate, is related to mucinous adenocarcinoma and prostate cancer. An important gene associated with Prostate Adenocarcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Endometrial cancer and DNA Damage Response (only ATM dependent). The drugs Lidocaine and Prilocaine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are endocrine/exocrine gland and limbs/digits/tail

Related Diseases for Prostate Adenocarcinoma

Diseases related to Prostate Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
id Related Disease Score Top Affiliating Genes
1 mucinous adenocarcinoma 29.8 AMACR AR KLK3 TMPRSS2
2 prostate cancer 24.2 AMACR AR BMP6 CHGA ERBB2 ESR2
3 lymphoepithelioma-like acinar prostate adenocarcinoma 11.9
4 prostatitis 11.0
5 adenocarcinoma 11.0
6 pulmonary vein leiomyosarcoma 10.9 CHGA KLK3
7 prostate colloid adenocarcinoma 10.8
8 hole retinal cyst 10.7 AR KLK3
9 malt worker's lung 10.7 KLK3 TP53
10 thymic dysplasia 10.7 AMACR KLK3
11 endometriosis 10.7 AR KLK3
12 pulmonary embolism and infarction 10.6 AR TP53
13 intraductal breast myoepitheliosis 10.6 CHGA TP53
14 gastric tubular adenocarcinoma 10.6 AR ERBB2
15 congenital granular cell tumor 10.6 CHGA TP53
16 congenital disorder of glycosylation, type if 10.5 ERBB2 TP53
17 breast myoepithelial neoplasm 10.5 PTEN TP53
18 ulceroglandular tularemia 10.5 AR ESR2
19 endocervicitis 10.5 ERBB2 TP53
20 gastroesophageal junction adenocarcinoma 10.5 AR ERBB2
21 pancreatic agenesis 10.5 CHGA KLK3 TP53
22 sarcomatoid renal cell carcinoma 10.5 AMACR KLK3 TP53
23 bowman's membrane folds or rupture 10.5 AR PTEN
24 her2-receptor positive breast cancer 10.5 ERBB2 ESR2
25 animal phobia 10.4 ERBB2 TP53
26 breast mucinous cystadenocarcinoma 10.4 AMACR UPK3A
27 gastrojejunal ulcer 10.4 AR ESR2
28 benign shuddering attacks 10.4 AR CHGA TP53
29 avoidant personality disorder 10.4 AR ESR2 KLK3
30 retinal disease 10.4 ERBB2 KLK3 TP53
31 farber lipogranulomatosis 10.4 AMACR GSTP1 TP53
32 group b strep disease in newborns 10.4 CHGA ERBB2 TP53
33 pituitary carcinoma 10.3 AMACR KLK3 UPK3A
34 osteogenesis imperfecta 10.3 AR ESR2
35 infratentorial cancer 10.3 AMACR AR FOLH1 KLK3
36 glycogen-rich clear cell breast carcinoma 10.3 AMACR KLK3 UPK3A
37 mediastinum seminoma 10.3 TP53 UPK3A
38 fibular collateral ligament bursitis 10.3 AMACR KLK3 UPK3A
39 vulva squamous cell carcinoma 10.3 ERBB2 UPK3A
40 rete testis adenoma 10.3 TP53 UPK3A
41 vulva adenocarcinoma 10.3 AR ERBB2 TP53
42 mixed cerebral palsy 10.3 AR ERBB2 TP53
43 superior vena cava angiosarcoma 10.3 AR ERBB2 TP53
44 brenner tumor of the vagina 10.3 ERBB2 PTEN TP53
45 brenner tumor of ovary 10.3 ERBB2 PTEN TP53
46 extracranial neuroblastoma 10.3 ERBB2 TP53
47 breast granular cell tumor 10.2 AR ERBB2 TP53
48 trachea squamous cell carcinoma 10.2 ERBB2 PTEN TP53
49 dubin-johnson syndrome 10.2 ERBB2 PTEN TP53
50 chest wall lymphoma 10.2 PTEN TP53

Graphical network of the top 20 diseases related to Prostate Adenocarcinoma:



Diseases related to Prostate Adenocarcinoma

Symptoms & Phenotypes for Prostate Adenocarcinoma

MGI Mouse Phenotypes related to Prostate Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.86 AR CHGA ERBB2 ESR2 MSMB PTEN
2 limbs/digits/tail MP:0005371 9.63 AR ERBB2 ESR2 PTEN TP53 WDR19
3 neoplasm MP:0002006 9.5 TP53 AR ERBB2 ESR2 MSMB PTEN
4 reproductive system MP:0005389 9.28 AR BMP6 CHGA ERBB2 ESR2 MSMB

Drugs & Therapeutics for Prostate Adenocarcinoma

Drugs for Prostate Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 390)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Prilocaine Approved Phase 4 721-50-6 4906
3
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Anesthetics Phase 4,Phase 2,Phase 3
6 Anesthetics, Local Phase 4
7 Anti-Arrhythmia Agents Phase 4
8 Central Nervous System Depressants Phase 4
9 Diuretics, Potassium Sparing Phase 4
10 Sodium Channel Blockers Phase 4
11 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
12 Cholinergic Agents Phase 4
13 Cholinergic Antagonists Phase 4
14 Muscarinic Antagonists Phase 4
15
Bicalutamide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 90357-06-5 56069 2375
16
Cyproterone Acetate Approved, Investigational Phase 3 427-51-0
17
Goserelin Approved Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
18
Flutamide Approved Phase 3,Phase 2,Phase 1 13311-84-7 3397
19
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
20
Estramustine Approved Phase 3,Phase 1,Phase 2 2998-57-4 18140 259331
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
22
Testosterone Approved, Investigational Phase 3,Phase 2,Phase 1 58-22-0 6013
23
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
24
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
25
Prednisone Approved, Vet_approved Phase 3,Phase 1,Phase 2 53-03-2 5865
26
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2 65271-80-9 4212
27
Methyltestosterone Approved Phase 3,Phase 2,Phase 1 58-18-4 6010
28
Leuprolide Approved, Investigational Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
29
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
30
Norepinephrine Approved Phase 3 51-41-2 439260
31
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
32
Ketoconazole Approved, Investigational Phase 3,Phase 2,Phase 1 65277-42-1 47576 3823
33
Nilutamide Approved Phase 3,Phase 2,Phase 1 63612-50-0 4493
34
Vinblastine Approved Phase 3,Phase 1,Phase 2 865-21-4 13342 241903
35
Buserelin Approved Phase 3,Phase 2,Phase 1 57982-77-1
36
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
37
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
39
Diethylstilbestrol Approved Phase 3 56-53-1 3054 448537
40
Suramin Approved Phase 3 145-63-1 5361
41
Zoledronic acid Approved Phase 3,Phase 2,Phase 1 118072-93-8 68740
42
Clodronate Approved, Investigational, Vet_approved Phase 3 10596-23-3 25419
43
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
44
Calcium Carbonate Approved Phase 3 471-34-1
45
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757
46
Celecoxib Approved, Investigational Phase 2, Phase 3,Phase 1 169590-42-5 2662
47
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
48
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
50
Salicylic acid Approved, Vet_approved Phase 2, Phase 3 69-72-7 338

Interventional clinical trials:

(show top 50) (show all 593)

id Name Status NCT ID Phase Drugs
1 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel anesthesia;periprostatic nerve blockade
2 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Active, not recruiting NCT01661166 Phase 4 Fesoterodine
3 Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy Terminated NCT01365143 Phase 4
4 A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel Unknown status NCT00764166 Phase 3 Docetaxel + hormonal treatment (LH-RH agonist);Hormonal treatment (LH-RH agonist)
5 Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer Unknown status NCT00363285 Phase 3 cyproterone acetate
6 Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer Unknown status NCT00104715 Phase 3 antiandrogen therapy;docetaxel;goserelin acetate
7 Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer Unknown status NCT00967863 Phase 3
8 Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer Unknown status NCT00392535 Phase 3 cyproterone acetate;releasing hormone agonist therapy
9 Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Unknown status NCT00376792 Phase 3 docetaxel
10 Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer Unknown status NCT00796458 Phase 3 docetaxel;releasing hormone agonist therapy
11 Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer Unknown status NCT00003734 Phase 3 flutamide;triptorelin
12 Androgen Deprivation Therapy in Treating Patients With Prostate Cancer Unknown status NCT00110162 Phase 3 antiandrogen therapy;releasing hormone agonist therapy
13 Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma Completed NCT01011751 Phase 3 Cyproterone acetate;Medroxyprogesterone acetate;Venlafaxine;Leuprorelin;Flutamide;Placebo
14 Image Guided Radiation Therapy For Prostate Cancer Completed NCT00433706 Phase 3
15 Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed NCT00002855 Phase 3 Bicalutamide;Doxorubicin hydrochloride;Estramustine Phosphate Sodium;Flutamide;Ketoconazole;Nilutamide;Therapeutic Hydrocortisone;Vinblastine
16 Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer Completed NCT00002633 Phase 3 bicalutamide;buserelin;flutamide;goserelin;leuprolide acetate;nilutamide
17 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed NCT00002597 Phase 3 flutamide;Zoladex;Lupron
18 Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer Completed NCT00003607 Phase 3
19 Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy Completed NCT00065442 Phase 3
20 A Study of Leuprolide to Treat Prostate Cancer Completed NCT00626431 Phase 3 Leuprolide acetate - Formulation A;Leuprolide acetate - Formulation B
21 Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer Completed NCT00394511 Phase 3
22 Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer Completed NCT00182052 Phase 3 Rosiglitazone
23 Study of Histrelin Subdermal Implant in Patients With Prostate Cancer Completed NCT01394263 Phase 3 Histrelin hydrogel implant;Zoladex goserelin implant
24 Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer Completed NCT01697384 Phase 3 histrelin acetate
25 Hormone Therapy in Treating Patients With Advanced Prostate Cancer Completed NCT00003026 Phase 3 bicalutamide;flutamide;triptorelin
26 Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer Completed NCT00657904 Phase 3 Bicalutamide;Placebo
27 A Long Term Safety Study With Atrasentan Completed NCT00127478 Phase 2, Phase 3 Atrasentan
28 Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer Completed NCT00003653 Phase 3 bicalutamide;buserelin;cyproterone acetate;flutamide;goserelin;leuprolide acetate;nilutamide
29 Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer Completed NCT00027859 Phase 3 docetaxel;estramustine phosphate sodium;ketoconazole;therapeutic hydrocortisone
30 Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer Completed NCT00067015 Phase 3 bicalutamide;goserelin acetate
31 Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer Completed NCT00002760 Phase 3 ketoconazole;therapeutic hydrocortisone
32 Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Completed NCT00110214 Phase 3 docetaxel;prednisone
33 Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer Completed NCT00316927 Phase 3 acetylsalicylic acid;dexamethasone;diethylstilbestrol
34 SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Completed NCT00002651 Phase 3 bicalutamide;goserelin acetate
35 S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy Completed NCT00004001 Phase 3 docetaxel;estramustine;mitoxantrone;prednisone
36 Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer Completed NCT00002881 Phase 3 flutamide;goserelin acetate;leuprolide acetate;suramin;therapeutic hydrocortisone
37 Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer Completed NCT00023686 Phase 3
38 Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Completed NCT00005947 Phase 3
39 Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer Completed NCT00255606 Phase 3 docetaxel;prednisone
40 Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer Completed NCT00062309 Phase 3
41 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed NCT00134056 Phase 3 atrasentan hydrochloride;docetaxel;prednisone
42 Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Completed NCT00002723 Phase 3 suramin;suramin;Suramin
43 Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed NCT00002703 Phase 3
44 Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Completed NCT00079001 Phase 3 zoledronic acid;androgen deprivation therapy;GnRH agonist
45 Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer Completed NCT00003232 Phase 3 clodronate disodium;mitoxantrone hydrochloride;prednisone
46 Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy Completed NCT00931528 Phase 3 Tadalafil
47 Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy Completed NCT01707966 Phase 3 Orteronel;Placebo
48 Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer Completed NCT00002511 Phase 3
49 Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer Completed NCT00423475 Phase 3 goserelin acetate
50 Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer Completed NCT00030654 Phase 3 bicalutamide;docetaxel;doxorubicin hydrochloride;estramustine phosphate sodium;flutamide;ketoconazole;paclitaxel;releasing hormone agonist therapy;vinblastine sulfate

Search NIH Clinical Center for Prostate Adenocarcinoma

Genetic Tests for Prostate Adenocarcinoma

Anatomical Context for Prostate Adenocarcinoma

MalaCards organs/tissues related to Prostate Adenocarcinoma:

39
Prostate, Bone, Lymph Node, Lung, Testes, Endothelial, Bone Marrow

Publications for Prostate Adenocarcinoma

Articles related to Prostate Adenocarcinoma:

(show top 50) (show all 821)
id Title Authors Year
1
Nonspecific granulomatous prostatitis in association with eosinophilic epithelial metaplasia and prostatic adenocarcinoma. ( 28937384 )
2017
2
Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. ( 28389666 )
2017
3
Incidental Prostate Adenocarcinoma in Cystoprostatectomy Specimens: Partial Versus Complete Prostate Sampling. ( 28381150 )
2017
4
Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach. ( 28377935 )
2017
5
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? ( 28191651 )
2017
6
Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma. ( 28521463 )
2017
7
Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma. ( 28552539 )
2017
8
Prostate adenocarcinoma metastases to the testis and brain: case report and review of the literature. ( 28845236 )
2017
9
Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma. ( 28888085 )
2017
10
Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes. ( 28716144 )
2017
11
Complete biochemical response after pulmonary metastasectomy in prostate adenocarcinoma. ( 28932626 )
2017
12
Testicular Metastasis From Prostatic Adenocarcinoma Presenting as Recurrent Epididymo-orchitis. ( 28760557 )
2017
13
Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2016. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.046. ( 28111115 )
2017
14
Differentiating tumor heterogeneity in formalin-fixed paraffin-embedded (FFPE) prostate adenocarcinoma tissues using principal component analysis of matrix-assisted laser desorption/ionization imaging mass spectral data. ( 27791282 )
2017
15
Overexpression of Aquaporin-1 is a Prognostic Factor for Biochemical Recurrence in Prostate Adenocarcinoma. ( 27817002 )
2017
16
Ductal variant of prostate adenocarcinoma harbor Xenotropic murine leukemia virus related virus (XMRV) infection: a novel finding in subtype of prostate cancer. ( 28861296 )
2017
17
Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma. ( 28107606 )
2017
18
Metastatic Prostate Adenocarcinoma to the Brain: Case Reports and Literature Review. ( 28352499 )
2017
19
Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. ( 28590015 )
2017
20
Epididymal metastasis from prostate adenocarcinoma: An unusual and challenging diagnosis suspected in gallium-68 prostate-specific membrane antigen-positron emission tomography/computed tomography and histologically confirmed. ( 28216940 )
2017
21
The role of nutrition in the prevention of prostatic adenocarcinoma. ( 28952237 )
2017
22
Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals. ( 28230260 )
2017
23
Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. ( 28881646 )
2017
24
Yes-Associated Protein Expression Is Correlated to the Differentiation of Prostate Adenocarcinoma. ( 28602051 )
2017
25
pCramoll and rCramoll lectins induce cell death in human prostate adenocarcinoma (PC-3) cells by impairment of mitochondrial homeostasis. ( 28552641 )
2017
26
Incomplete cavernous sinus syndrome as the initial manifestation of a previously undetected metastatic prostate adenocarcinoma. ( 28474478 )
2017
27
An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography (18)F-FLT PET/CT in Prostate Adenocarcinoma. ( 28375169 )
2017
28
Risk of lymph node metastases in pathological gleason scorea8o6 prostate adenocarcinoma: Analysis of institutional and population-based databases. ( 27692833 )
2017
29
Treatment-naA^ve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect. ( 28587951 )
2017
30
Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and AbraxaneAr for treatment of human prostate adenocarcinoma in mice. ( 27297780 )
2016
31
Role of tumor-associated macrophages in the Hexim1 and TGFI^/SMAD pathway, and their influence on progression of prostatic adenocarcinoma. ( 26608417 )
2016
32
Prognostic Significance of Lymphatic Vessel Density Detected by D2-40 and Its Relation to Claudin-4 Expression in Prostatic Adenocarcinoma. ( 26464161 )
2016
33
(64)Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. ( 27715146 )
2016
34
Beyond Prostate Adenocarcinoma: Expanding the Differential Diagnosis in Prostate Pathologic Conditions. ( 27315446 )
2016
35
Metastasis of Prostate Adenocarcinoma to the Testis. ( 27703299 )
2016
36
Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. ( 26818960 )
2016
37
Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. ( 27753182 )
2016
38
Evaluation of survivin expression in prostate specimens of patients with prostate adenocarcinoma and benign prostate hyperplasia underwent transurethral resection of the prostate or prostatectomy. ( 27330887 )
2016
39
Metastatic prostate adenocarcinoma presenting as a large right supraclavicular and anterior chest wall mass. ( 27799225 )
2016
40
Docetaxel-Related Toxic Optic Neuropathy in Management of Prostate Adenocarcinoma. ( 27527400 )
2016
41
Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT. ( 27824323 )
2016
42
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. ( 27180064 )
2016
43
Bilateral Testicular Metastases and Filariasis in Prostatic Adenocarcinoma. ( 28017535 )
2016
44
Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming. ( 26773436 )
2016
45
Reduced expression of the DNA glycosylase gene MUTYH is associated with an increased number of somatic mutations via a reduction in the DNA repair capacity in prostate adenocarcinoma. ( 27253753 )
2016
46
Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria. ( 27486316 )
2016
47
MULTIMODAL IMAGING AND HISTOLOGIC CORRELATION OF ISOLATED METASTASIS OF PROSTATE ADENOCARCINOMA TO THE CHOROID. ( 27124795 )
2016
48
mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. ( 27096957 )
2016
49
Metastasis of prostate adenocarcinoma to the frontal and ethmoid sinus. ( 27909626 )
2016
50
A Signaling Network Controlling Androgenic Repression of c-Fos Protein in Prostate Adenocarcinoma Cells. ( 26786102 )
2016

Variations for Prostate Adenocarcinoma

ClinVar genetic disease variations for Prostate Adenocarcinoma:

6 (show top 50) (show all 64)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
7 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
9 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
10 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
11 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
12 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
13 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
14 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
15 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
16 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
17 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
18 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
19 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
20 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
21 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
22 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
23 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
24 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
25 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
26 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
27 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
28 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
29 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
30 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
31 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
32 CTNNB1 NM_001904.3(CTNNB1): c.122C> T (p.Thr41Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913413 GRCh37 Chromosome 3, 41266125: 41266125
33 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
34 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh37 Chromosome 3, 41266136: 41266136
35 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
36 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980
37 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
38 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
39 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
40 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
41 BRAF NM_004333.4(BRAF): c.1790T> A (p.Leu597Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
42 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
43 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
44 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
45 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh38 Chromosome 17, 7675190: 7675190
46 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
47 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
48 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
49 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
50 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093

Expression for Prostate Adenocarcinoma

Search GEO for disease gene expression data for Prostate Adenocarcinoma.

Pathways for Prostate Adenocarcinoma

GO Terms for Prostate Adenocarcinoma

Cellular components related to Prostate Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 AIMP1 BMP6 CHGA ESR2 GSTP1 KLK3

Biological processes related to Prostate Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-mediated signaling GO:0048015 9.43 ERBB2 PTEN TP53
2 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.16 AR ERBB2
3 cell proliferation GO:0008283 9.02 AR ERBB2 GRPR PTEN TP53
4 prostate gland growth GO:0060736 8.96 AR PTEN

Sources for Prostate Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....